Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Pharmafina Ilac Satis Ve Pazarlama Anonim Sirketi operates within the Biotechnology & Pharmaceuticals technology area and currently has 1 pending office action. This action is being reviewed by 1 distinct examiner, indicating a focused prosecution footprint. The involvement of only 1 distinct art unit further confirms that the company's current patent efforts are concentrated within a specific technical domain. This allows the legal team to develop a highly specialized narrative that aligns with the standards of that particular examination group at the USPTO.
The busiest examiner for the portfolio is CORNET, JEAN P, who is responsible for the 1 busiest examiner pending office action. Because this individual is the only examiner currently reviewing the company's applications, as shown by the 1 distinct examiner count, their interpretation of the pharmaceutical prior art will be the decisive factor. Practitioners can benefit from this arrangement by focusing their resources on a single point of contact. This centralized approach can lead to more consistent outcomes across the pending portion of the portfolio.
With 1 pending office action active, the portfolio's current workload is manageable and highly targeted. The fact that the 1 distinct examiner is also the busiest examiner means that the company's primary goal is to satisfy the requirements of CORNET, JEAN P. This singular focus within 1 distinct art unit reduces the need to track multiple deadlines and varying examiner styles, streamlining the overall patent acquisition process for the company's pharmaceutical innovations.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CORNET, JEAN P | 1 | 41.9% | +47.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18017860 | COMBINATION OF MEDICATIONS IN A PARENTERAL DOSAGE FORM FOR LONG-TERM ANAESTHESIA | CORNET, JEAN P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18017860 | COMBINATION OF MEDICATIONS IN A PARENTERAL DOSAGE FORM FOR LONG-TERM ANAESTHESIA | CORNET, JEAN P | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18017860 | COMBINATION OF MEDICATIONS IN A PARENTERAL DOSAGE FORM FOR LONG-TERM ANAESTHESIA | CORNET, JEAN P | 1628 | §103§112 | Final Rejection | — | Pending | Jan 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPharmafina Ilac Satis Ve Pazarlama Anonim Sirketi has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jean P Cornet has the most, with 1 of Pharmafina Ilac Satis Ve Pazarlama Anonim Sirketi's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.